Dayna Jett
Family Medicine · Springfield, MONPI 1942640305
Payments from drug & device makers
Across 93 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$258
- Pfizer$254
- Merck$197
- AbbVie$129
- Otsuka America Pharmaceutical, Inc.$122
- Organon$103
- plus $631 from 14 others
What the payments were for
- Food & beverage$1,694100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $258 |
| Pfizer | 16 | $254 |
| Merck | 13 | $197 |
| AbbVie | 5 | $129 |
| Otsuka America Pharmaceutical, Inc. | 6 | $122 |
| Organon | 7 | $103 |
| Lilly USA, LLC | 6 | $99 |
| Gilead | 1 | $88 |
| AstraZeneca | 6 | $87 |
| Lundbeck LLC | 3 | $63 |
| Corium, LLC | 2 | $63 |
| Astellas Pharma US Inc | 3 | $59 |
| Bayer | 2 | $30 |
| Exact Sciences | 2 | $30 |
| GSK | 2 | $29 |
| Shield Therapeutics Inc | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,694 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $41,718 |
| JardianceEmpagliflozin | 27 | $30,309 |
| MounjaroTirzepatide | 13 | $13,324 |
| XareltoRivaroxaban | 13 | $11,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,594 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,818 |
| Atorvastatin Calcium | 191 | $1,256 |
| Duloxetine Hcl | 47 | $1,221 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,188 |
| Potassium Chloride | 44 | $1,047 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $1,024 |
| Gabapentin | 90 | $1,021 |
| Levothyroxine Sodium | 128 | $955 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $906 |
| Pantoprazole Sodium | 80 | $866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $258 | $41,71844 claims |
| Lilly USA, LLCMounjaro | $99 | $13,32413 claims |
| GSKTrelegy Ellipta, Shingrix | $29 | $11,41226 claims |
| AbbVieSynthroid | $129 | $69814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Springfield
- William HowittSpringfield$19.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Stephen AdamsSpringfield$636K
- Cory BethmannSpringfield$621K
- Roger CadySpringfield$175K
- Don BrockmanSpringfield$31K
- James van RiessenSpringfield$25K
- Timothy JenningsMaryland Heights$30.2M
- Rupal TrivediSaint Louis$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.